Introduction {#Sec1}
============

Acne is the most prevalent skin disease in the world, affecting 85% of adolescents and over 10% of adults \[[@CR1]\]. In the USA, it represents a tremendous economic burden with total costs exceeding \$3 billion per year \[[@CR2]\]. Antibiotics are efficient against sensitive *Propionibacterium acnes,* but resistance has developed due to monotherapy and overuse \[[@CR3]\]. Other treatments such as retinoids and benzoyl peroxide are limited by patient compliance due to undesirable side effects such as irritation \[[@CR4]\]. Benzoyl peroxide is highly effective as an antimicrobial in vitro \[[@CR5]\] and in vivo \[[@CR6]\], and it is a first-line drug for the treatment of acne due to its direct bactericidal and comedolytic properties. Although no known bacterial resistance has been reported to benzoyl peroxide \[[@CR7], [@CR8]\], its side effects still limit its use. Thus, the need exists for new efficacious treatments with fewer side effects. Already, newer topical combination therapies have been developed to reduce the concentration of benzoyl peroxide through its combination with other anti-acne compounds \[[@CR9]\].

Resveratrol (3,5,4′-trihydroxystilbene) may be a useful anti-acne treatment. It is a potent antioxidant and anti-inflammatory compound that has been shown to have antineoplastic and wound-healing activities \[[@CR10]\]. It has been demonstrated to inhibit inflammatory markers activation protein-1 (AP-1) and nuclear factor-kappaB (NF-κB), both of which have been implicated in the formation of inflammatory acne lesions \[[@CR11]\]. Resveratrol is also antimicrobial, demonstrating antiviral, antifungal, antibacterial, and antiprotozoal activity \[[@CR12]--[@CR14]\], and has been shown to inhibit keratinocyte proliferation, which contributes to follicular obstruction in the formation of acne lesions \[[@CR15]\]. Few studies have evaluated resveratrol's application as a treatment for acne vulgaris, although one clinical study has previously demonstrated the potential efficacy of resveratrol in the treatment of acne vulgaris \[[@CR16]\]. Additionally, an in vitro study showed that resveratrol has antimicrobial activity against *P. acnes* \[[@CR17]\].

The present study further investigated the potential of resveratrol as a treatment for acne. It sought to determine the in vitro effects of resveratrol on *P. acnes* growth and survival, while further assessing the antimicrobial mechanism of action of resveratrol and its cytotoxic effects. It also determined the efficacy of utilizing resveratrol as part of a combination therapy with benzoyl peroxide.

Methods {#Sec2}
=======

Reagents {#Sec3}
--------

Resveratrol and benzoyl peroxide were obtained from Sigma-Aldrich (St. Louis, MO, USA). The compounds were dissolved in dimethyl sulfoxide (DMSO) and diluted to 1% DMSO in experiments, to minimize the effect of DMSO.

Colony-Forming Unit assay {#Sec4}
-------------------------

Antibacterial activity of resveratrol was determined by colony-forming unit (CFU) assays. *P. acnes* ATCC (American type cell culture) strain 6919 (a ribotype 1 \[[@CR18]\] MLST4 1A~1~ strain \[[@CR19]\]) was grown anaerobically at 37 °C in reinforced clostridial media (Oxoid, Basingstoke, Hampshire, UK) for 3 days and collected in the late exponential phase of growth by centrifugation. Bacteria were washed with pH 7 sodium phosphate buffer supplemented by 0.03% trypticase soy media and quantified by reading with a spectrophotometer at 600 nm and applying a conversion of 1 × 10^8^ bacteria = 1 absorbance unit. Approximately, 1.33 × 10^6^ CFUs of bacteria were then added to 1 mL reinforced clostridial media. Samples were incubated anaerobically at 37 °C, with aliquots periodically withdrawn and plated on brucella agar with 5% sheep blood supplemented with hemin and vitamin K (Remel, Lenexa, KS, USA). Plates were incubated anaerobically at 37 °C for 3 days, and individual *P. acnes* colonies were counted to determine the concentration.

Electron Microscopy {#Sec5}
-------------------

*Propionibacterium acnes* at 10^7^ CFU/mL were incubated with either 1 mg/mL of resveratrol or benzoyl peroxide for 24 h. Bacteria were washed three times with phosphate buffered saline (PBS) and resuspended in PBS with 2% glutaraldehyde. Samples were fixed for 5 min with 0.05% OsO~4~, dehydrated in graded ethanol, and embedded in Eponate 12 (Ted Pella, Redding, CA, USA). A Reichert-Jung Ultracut E ultramicrotome™ (Leica, Buffalo Grove, IL, USA) was used to cut 60--70 nm slices which were picked up on formvar-coated copper grids. Uranyl acetate and Reynolds lead citrate were used for staining, and stained samples were visualized at 80 kV on a JEOL 100CX electron microscope™ (Peabody, MI, USA).

MTS Assay {#Sec6}
---------

Blood was drawn from healthy human volunteers recruited by the laboratory with no skin conditions, including acne, and who had not suffered any illness within 2 weeks of the blood draw date. Peripheral blood mononuclear cells were isolated by use of a Ficoll-Paque (Pharmacia, New York, NY, USA) gradient and allowed to adhere for 2 h in RPMI media (Gibco, Grand Island, NY, USA) supplemented with 1% fetal bovine serum (FBS) (Omega Scientific, Tarzana, CA, USA) in 96-well plates (Costar, Tewksbury, MA, USA). Cells were washed 3× with Roswell Park Memorial Park Institute (RPMI) media to obtain adherent monocytes. Monocytes were then incubated at 37 °C in 100 μL RPMI media supplemented with 10% FBS. The HaCaT cell line of human keratinocytes was cultured in 100 μL HaCaT media and incubated at 37 °C in 96-well plates (Costar). To evaluate human monocyte and human keratinocyte viability after incubation with resveratrol or benzoyl peroxide, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cytotoxicity assays were performed. After 16 h of incubation with resveratrol or benzoyl peroxide, 20 μL MTS assay reagent (Promega, Madison, WI, USA) was added to each well, and the monocyte and keratinocyte cells were allowed to incubate for \~4 h at 37 °C. The 490 nm absorbance of each well was then determined using a microtiter plate reader, with absorbance proportional to the number of viable monocyte and keratinocyte cells in each treatment, as previously described \[[@CR20]\]. Student's *T* test was used for statistical analysis to determine if differences between resveratrol and benzoyl peroxide-treated cells were significant.

Compliance with Ethics Guidelines {#Sec7}
---------------------------------

Study protocol for withdrawal of blood from healthy volunteers was approved by the Institutional Review Board at the University of California, Los Angles. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients for being included in the study.

Results {#Sec8}
=======

Resveratrol has Antibacterial Activity Against *P. acnes* {#Sec9}
---------------------------------------------------------

The effect of resveratrol on *P. acnes* growth was visually demonstrated by incubating *P. acnes* bacteria with various concentrations of resveratrol for 48 h in reinforced clostridial media before spot plating. At a concentration of at least 50 μg/mL, resveratrol demonstrated significant inhibition of *P. acnes* growth (Fig. [1](#Fig1){ref-type="fig"}). Resveratrol at 25 μg/mL had only a small inhibitory effect.Fig. 1Resveratrol has antimicrobial activity against *P. acnes*. *Propionibacterium acnes* was incubated with various concentrations of resveratrol for 48 h and plated at different dilutions demonstrating reduced bacterial colony count at higher concentrations of resveratrol

Resveratrol and Benzoyl Peroxide have Different Antibacterial Characteristics {#Sec10}
-----------------------------------------------------------------------------

To determine the antibacterial kinetics of resveratrol, benzoyl peroxide, and a combination of both on *P. acnes* growth, *P. acnes* was incubated with these treatments in reinforced clostridial media, and the concentration of bacteria was determined after 1, 2, 3, 7, and 10 days. Resveratrol demonstrated low bactericidal activity, but significant and sustained growth inhibition at concentrations of 100 μg/mL and shorter term growth inhibition at 50 μg/mL (Fig. [2](#Fig2){ref-type="fig"}a).Fig. 2Antimicrobial effects of resveratrol and benzoyl peroxide over time. *P. acnes* was incubated in reinforced clostridial media in the presence of resveratrol (**a**), benzoyl peroxide (**b**), or a combination of both treatments (**c**). Aliquots were removed at several time points and plated in triplicate to determine the number of CFUs. A comparison of each treatment group at 75 µg/mL is also displayed (**d**). *CFU* colony-forming unit

In contrast, benzoyl peroxide demonstrated significant differences in bactericidal kinetics when compared to resveratrol. High bactericidal activity was noted initially, but there was no antibacterial activity observed after the first 24 h (Fig. [2](#Fig2){ref-type="fig"}b). *P. acnes* recovered from benzoyl peroxide treatment and achieved maximum growth rate by the second day, irrespective of benzoyl peroxide concentration. Results from the combination therapy of resveratrol and benzoyl peroxide reflected the antibacterial kinetics of each individual treatment (Fig. [2](#Fig2){ref-type="fig"}c). As demonstrated with benzoyl peroxide alone, the combination treatment showed high initial antibacterial activity. Combination treatment also demonstrated the longer term inhibitory effects shown by resveratrol monotherapy. Combination therapy, therefore, resulted in a much lower concentration of *P. acnes* over the course of the study than with either treatment alone.

A comparison of each treatment group at a concentration of 75 μg/mL highlighted the short-term bactericidal activity of benzoyl peroxide, the sustained inhibitory activity of resveratrol, and the enhanced activity of resveratrol and benzoyl peroxide combination therapy (Fig. [2](#Fig2){ref-type="fig"}d).

Resveratrol Alters the Membrane and Structure of *P. acnes* {#Sec11}
-----------------------------------------------------------

To further investigate the mechanism by which resveratrol inhibits *P. acnes* growth, this study examined the bacterium using transmission electron microscopy (Fig. [3](#Fig3){ref-type="fig"}). Structural alterations were noted in the bacteria treated with resveratrol, with loss of membrane definition due to intramembranous edema and loss of well-defined extracellular fimbrial structures. Intracellular buildup of a dense substance was also found in some bacteria treated with resveratrol.Fig. 3Electron microscopy demonstrating antimicrobial effect of resveratrol. Electron microscopy images of *P. acnes* left untreated (**a**, **b**) or incubated for 24 h (**c**, **d**) with resveratrol. Images were taken at ×10,000 magnification (**a**, **c**) or ×29,000 magnification (**b**, **d**). *Scale bar* is 1 µm (**a**, **c**) or 1/2 µm (**b**, **d**)

Resveratrol has Lower Cytotoxicity than Benzoyl Peroxide to Human Monocytes and Keratinocytes {#Sec12}
---------------------------------------------------------------------------------------------

This study evaluated the cytotoxic effects of benzoyl peroxide compared to resveratrol via the MTS assay for human monocytes (Fig. [4](#Fig4){ref-type="fig"}a) and keratinocytes (Fig. [4](#Fig4){ref-type="fig"}b). Benzoyl peroxide was significantly more toxic than resveratrol to monocytes (*p* \< 0.001 for all concentrations tested, Student's *t* test), resulting in over 90% cell death at 10 μg/mL, while resveratrol resulted in less than 40% cell death at the same concentration. These effects were less pronounced in keratinocytes (*p* \< 0.01 for all concentrations tested, Student's *t* test), where both compounds had lower cytotoxicity. Nonetheless, benzoyl peroxide treatment resulted in 20--30% more cell death at all concentrations tested in keratinocytes.Fig. 4Cytotoxicity of benzoyl peroxide and resveratrol. Primary human monocytes (**a**) or keratinocytes (**b**) were incubated with resveratrol and benzoyl peroxide for 16 h. The percentages of viable cells were assessed in triplicate by MTS assay. Statistics show comparison between resveratrol and benzoyl peroxide group at each concentration by Student's *t* test, \*\*(*p* \< 0.01), \*\*\*(*p* \< 0.001)

Discussion {#Sec13}
==========

Acne vulgaris is the most common skin disease, affecting millions of people worldwide \[[@CR21]\].

Unfortunately, bacterial antibiotic resistance and severe side effects limit the efficacy of current treatments \[[@CR22]\].

Resveratrol has a favorable safety profile and is an anti-inflammatory and antimicrobial compound. Thus, this study investigated the potential of resveratrol as an antibacterial agent for the treatment for acne vulgaris.

The results from this study demonstrated the strong antibacterial activity of resveratrol at concentrations of at least 50 μg/mL (Fig. [1](#Fig1){ref-type="fig"}). These findings are consistent with prior studies which have demonstrated inhibition of *P. acnes* biofilm formation at slightly higher concentrations of 200 μg/mL \[[@CR23]\]. By further investigating the nature of this antibacterial activity, we found that resveratrol is bacteriostatic in nature, possessing strong inhibitory activity that limits the growth of *P. acnes* (Fig. [2](#Fig2){ref-type="fig"}a). Its bactericidal activity was relatively weak in terms of reduction of viable bacteria, but the antibacterial activity was sustained over time. This indicates that resveratrol creates a gradual disruption of normal bacterial cellular function, resulting in cell death over a period of several days. Our findings suggest that resveratrol reaches a critical concentration around 50--75 μg/mL, at which point a threshold for major growth inhibition is passed and resveratrol becomes bactericidal for a sustained period. In contrast, benzoyl peroxide's bactericidal activity was strong initially, but was not sustained beyond the first 24 h (Fig. [2](#Fig2){ref-type="fig"}b). This is in accordance with benzoyl peroxide's mechanism of action, whereby free radicals are formed via symmetrical fission, resulting in a short half-life \[[@CR24]\].

When both resveratrol and benzoyl peroxide were combined, benzoyl peroxide's strong bactericidal effect coupled with resveratrol's high inhibitory activity resulted in low levels of bacteria throughout the experiment (Fig. [2](#Fig2){ref-type="fig"}c). Thus, this combination shows promise for clinical treatment of acne vulgaris.

Electron microscopy of *P. acnes* treated with resveratrol revealed altered bacterial morphology, with the bacteria displaying intramembranous edema and disrupted intracellular structural integrity (Fig. [3](#Fig3){ref-type="fig"}). As a membrane permeable compound, this innate characteristic of resveratrol may allow it to alter the bacterial membrane structure of *P. acnes* and disrupt intracellular machinery.

Benzoyl peroxide was found to be highly cytotoxic to monocytes and keratinocytes, potentially explaining the irritation found with topical benzoyl peroxide regimens (Fig. [4](#Fig4){ref-type="fig"}). Resveratrol was significantly less cytotoxic, which may translate to decreased irritation in vivo. A pilot study investigating topical resveratrol treatment in acne found no cutaneous side effects from resveratrol \[[@CR16]\]. Additionally, one study demonstrated that macrophages treated with resveratrol maintained viability via a toll-like receptor 4 (TLR4)-dependant mechanism if also treated with lipopolysaccharide \[[@CR25]\], indicating that resveratrol may be less cytotoxic to cells in the presence of *P. acnes*.

A combination therapy of resveratrol and benzoyl peroxide may allow for a significant reduction of the benzoyl peroxide concentration compared to current benzoyl peroxide-based treatments, minimizing side effects. However, this study was in vitro, which does not necessarily translate to success in the clinic. Concentrations used in vitro may not accurately reflect effective in vivo concentrations necessary for the treatment of acne vulgaris. In vivo studies are needed to evaluate the efficacy of resveratrol and benzoyl peroxide in combination for the treatment of acne vulgaris.

Conclusion {#Sec14}
==========

Resveratrol's anti-inflammatory and antibacterial properties demonstrated here in vitro may address some of the pathogenic mechanisms in the formation of acne. Already, clinical studies have shown the beneficial effects of resveratrol in the treatment of acne \[[@CR16]\]. However, acne is a multifactorial disease, attributed also to sebum production \[[@CR26]\], which is not currently known to be addressed by resveratrol, and which may therefore limit its use as a monotherapy in the treatment of acne. Since resveratrol and benzoyl peroxide operate with different antibacterial kinetics and mechanisms, they may complement each other in a combination treatment in vivo, leading to enhanced clinical outcomes. Overall, the data in this study indicates that resveratrol may be a novel therapeutic option or useful adjuvant therapy for the treatment of acne vulgaris.
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